June 2009
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p11
The article reports on the Orphan Drug designation granted by the U.S. Food and Drug Administration (FDA) for Paclical from Oasmia Pharmaceutical AB to treat ovarian cancer. This designation is expected to entail additional assistance from the agency in optimizing development of drug. Meanwhile , a Phase III study that compares the Paclical's use to its generic equivalent is conducted by Oasmia.


Related Articles

  • FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer.  // Biomedical Market Newsletter;5/5/2011, p753 

    The article reports on the orphan drug status granted to Nektar Therapeutics' NKTR-102 oncology drug for treating women with ovarian cancer by the U.S. Food and Drug Administration (FDA). Nektar senior vice president Lorianne Masuoka considers the designation a critical measure in the...

  • Changes and Challenges at FDA. Wechsler, Jill // Pharmaceutical Executive;Oct2012, Vol. 32 Issue 10, p14 

    The article reports that new user fee programs are being established by the U.S. Food & Drug Administration (FDA) and a host of provisions authorized by the FDA Safety & Innovation Act (FDASIA) are being implemented. It is noted that critics continue to complain that "fast track," "priority...

  • Pipeline preview.  // Formulary;Feb2013, Vol. 48 Issue 2, p53 

    The article reports on consideration which the U.S. Food and Drug Administration is giving in 2013 to approving the drug Rytary for treating Parkinson's disease. A discussion of drugs, including Elafin, Ezatiostat and Enobosarm, which the agency has given fast track, priority review or orphan...

  • FDA Proposes Question-Based Review System for Generics. Bush, Laura // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p24 

    Reports that the US Food and Drug Administration's Office of Generic Drugs is developing a question-based review system for its chemistry, manufacturing, and controls evaluation of abbreviated new drug applications. Review of generic drugs; Improvement of manufacturing processes.

  • First-time generic approvals.  // Formulary;Feb2004, Vol. 39 Issue 2, p80 

    Presents first-time generic approvals by the U.S. Food and Drug Administration as of February 2004. Fenoldopam injection; Amiodarone tablets; Amoxicillin tablets; Others.

  • FDA: Many barriers remain on generic biologics. Vecchione, Anthony // Drug Topics;7/24/2006, Vol. 150 Issue 14, p32 

    Information about several issues discussed at a conference on the roles of the U.S. Food and Drug Administration is presented. The agency is trying to seek ways to make the process of developing generics more predictable and transparent for generic drug developers. It aims to develop better...

  • How Regulation of Medicine is Bankrupting the United States and What Congress Can Do to Stop It. FALOON, WILLIAM // Life Extension;Oct2011, Vol. 17 Issue 10, p7 

    In this article the author discusses medical care costs in the U.S. and the impact that the increasing cost of medical care is having on U.S. consumers and on Medicare. He is critical of the U.S. government's handling of its own health care system and suggests that the regulation of medicine is...

  • Biotech Innovation Boosts Orphan Drug Development. Wechsler, Jill // BioPharm International;Jul2008, Vol. 21 Issue 7, p16 

    The article focuses on the economic incentives and regulatory flexibility that the orphan drug (OD) program has presented, which can stimulate development of treatments for small patient populations in the U.S. It cites that a new priority review voucher program established by the Food and Drug...

  • Patients, Investigators Seek Flexibility at FDA. Wechsler, Jill // Applied Clinical Trials;Nov2011, Vol. 20 Issue 11, p20 

    The article focuses on the regulatory flexibility measures being conducted by the U.S. Food and Drug Administration (FDA) to address drug shortages. It says that FDA provide higher cost of drug development to speed new product to market and thus address short-supply drugs and research and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics